FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553691008> ?p ?o ?g. }

• W2553691008 abstract "Introduction Teduglutide (TED) is indicated for the treatment of adults with intestinal failure associated with short bowel syndrome (SBS-IF) who are dependent on parenteral support (PS). In phase III randomised placebo-controlled trials, TED significantly reduced PS volume requirements and number of PS infusion days per week in patients (pts) with SBS-IF. Here, we present combined safety data from TED-treated pts in these trials and their respective open-label extension studies. Methods Safety data were pooled from 4 TED clinical studies in adult pts with SBS–IF: two 24 week, double-blind, placebo-controlled trials with 2 respective open-label extensions of 28 weeks’ and 2 years’ duration (NCT-00081458, -00798967, -00172185, -0930644). Results Across 4 studies, 173 pts received subcutaneous TED (0.05 mg/kg/d, n = 134; 0.10 mg/kg/d, n = 39). 140 (81%) were treated with TED for ≥6 months and 111 (64%) were treated for ≥12 months; mean duration of TED exposure was 67 weeks. Most pts (97%) experienced ≥1 treatment-emergent adverse event (TEAE); the majority were mild (53%) or moderate (38%) in severity. TEAEs reported by ≥10% of pts were 42% abdominal pain; 29% upper respiratory tract infection; 27% catheter sepsis or nausea; 20% headaches or asthenic conditions; 19% injection-site reactions; 18.5% abdominal distension or urinary tract infections; 18% gastrointestinal (GI) stoma complications; 17% catheter site–related reactions or febrile disorders; and ≤15% vomiting, musculoskeletal pain, diarrhoea, fluid overload, hypersensitivity, or flatulence. The incidence rates of the most commonly reported GI adverse events (AEs) and fluid overload decreased over treatment time (Table) . TEAEs that led to premature discontinuation occurred in 20% of pts (n = 34); the most common was abdominal pain (5%; n = 8). Serious AEs (SAEs) were reported by 58% of pts (n = 101). The only SAE reported in ≥5% of TED-treated pts was catheter sepsis (25%; n = 43). As previously reported, 3 cases of malignant neoplasms occurred (metastatic adenocarcinoma, non–small-cell lung cancer, and squamous cell carcinoma). Metastatic adenocarcinoma was considered treatment related; this pt also had a history of Hodgkin disease treated with chemotherapy and radiation. Conclusion TED was generally well tolerated in pts with SBS-IF. No new safety signals were identified in the pooled analysis. The most frequently reported AEs were consistent with the underlying disease condition and known mechanism of action of TED and were reported early in the treatment period. Data from phase III trials demonstrate the safety of long-term TED treatment. Disclosure of Interest None Declared" @default.
• W2553691008 created "2016-11-30" @default.
• W2553691008 creator A5006625440 @default.
• W2553691008 creator A5022028752 @default.
• W2553691008 creator A5023178459 @default.
• W2553691008 creator A5033840493 @default.
• W2553691008 creator A5034922182 @default.
• W2553691008 creator A5043694977 @default.
• W2553691008 date "2016-06-01" @default.
• W2553691008 modified "2023-10-03" @default.
• W2553691008 title "PTU-110 Long-Term Safety of Teduglutide Treatment for Patients with Intestinal Failure Associated with Short Bowel Syndrome: Pooled Data from 4 Clinical Trials" @default.
• W2553691008 doi "https://doi.org/10.1136/gutjnl-2016-312388.196" @default.
• W2553691008 hasPublicationYear "2016" @default.
• W2553691008 type Work @default.
• W2553691008 sameAs 2553691008 @default.
• W2553691008 citedByCount "0" @default.
• W2553691008 crossrefType "journal-article" @default.
• W2553691008 hasAuthorship W2553691008A5006625440 @default.
• W2553691008 hasAuthorship W2553691008A5022028752 @default.
• W2553691008 hasAuthorship W2553691008A5023178459 @default.
• W2553691008 hasAuthorship W2553691008A5033840493 @default.
• W2553691008 hasAuthorship W2553691008A5034922182 @default.
• W2553691008 hasAuthorship W2553691008A5043694977 @default.
• W2553691008 hasConcept C126322002 @default.
• W2553691008 hasConcept C141071460 @default.
• W2553691008 hasConcept C142724271 @default.
• W2553691008 hasConcept C197934379 @default.
• W2553691008 hasConcept C204787440 @default.
• W2553691008 hasConcept C27081682 @default.
• W2553691008 hasConcept C2778715236 @default.
• W2553691008 hasConcept C2780580376 @default.
• W2553691008 hasConcept C2780852908 @default.
• W2553691008 hasConcept C2780955771 @default.
• W2553691008 hasConcept C535046627 @default.
• W2553691008 hasConcept C71924100 @default.
• W2553691008 hasConcept C90924648 @default.
• W2553691008 hasConceptScore W2553691008C126322002 @default.
• W2553691008 hasConceptScore W2553691008C141071460 @default.
• W2553691008 hasConceptScore W2553691008C142724271 @default.
• W2553691008 hasConceptScore W2553691008C197934379 @default.
• W2553691008 hasConceptScore W2553691008C204787440 @default.
• W2553691008 hasConceptScore W2553691008C27081682 @default.
• W2553691008 hasConceptScore W2553691008C2778715236 @default.
• W2553691008 hasConceptScore W2553691008C2780580376 @default.
• W2553691008 hasConceptScore W2553691008C2780852908 @default.
• W2553691008 hasConceptScore W2553691008C2780955771 @default.
• W2553691008 hasConceptScore W2553691008C535046627 @default.
• W2553691008 hasConceptScore W2553691008C71924100 @default.
• W2553691008 hasConceptScore W2553691008C90924648 @default.
• W2553691008 hasLocation W25536910081 @default.
• W2553691008 hasOpenAccess W2553691008 @default.
• W2553691008 hasPrimaryLocation W25536910081 @default.
• W2553691008 isParatext "false" @default.
• W2553691008 isRetracted "false" @default.
• W2553691008 magId "2553691008" @default.
• W2553691008 workType "article" @default.